NCT07308236 A Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male Participants
| NCT ID | NCT07308236 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Eisai Inc. |
| Condition | Healthy Volunteers |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2025-12-31 |
| Primary Completion | 2026-02-23 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The primary purpose of this study is to determine the metabolism and excretion of \[14C\]E2086 in healthy male participants.
Eligibility Criteria
Inclusion Criteria: 1. Non-smoking and non-vaping, healthy male, age greater than or equal to (\>=) 18 years and less than or equal to (\<=) 55 years old at the time of informed consent 2. Body Mass Index (BMI) \>=18 and less than (\<) 30 kilogram per square meter (kg/m\^2) at Screening 3. Provide written informed consent 4. Willing and able to comply with all aspects of the protocol Exclusion Criteria: 1. Have previously been dosed in more than 2 radiolabeled drug studies in the past 12 months. For participants who have previously been dosed in 2 or more radiolabeled drug studies within the last 12 months, the previous radiolabeled dose must be at least 4 months prior to check-in to the trial site where exposures are known to the investigator, or 6 months prior to check-in to the trial site for a radiolabeled drug trial where exposures are not known to the investigator. The total 12-month exposure from this trial and a maximum of 2 other previous radiolabeled studies must be within th